{"filing":{"accession_number":"0001654954-26-006803","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-07-23","report_date":null,"primary_document":"a5622n.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426006803/a5622n.htm"},"events":[{"id":19732,"run_id":17755,"accession_number":"0001654954-26-006803","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces European Commission approval of Etcamah (camizestrant) in combination with CDK4/6 inhibitors for first-line ER-positive breast cancer, based on positive Phase III SERENA-6 trial results showing a 56% reduction in disease progression or death risk. This is a material regulatory milestone and product approval that would affect investor assessment of AstraZeneca's oncology pipeline and commercial prospects, but does not fit the discrete event categories (it is neither an earnings release, M\u0026A activity, nor a specific financial/governance event). The approval represents a significant operational and commercial achievement for the company's oncology business.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-07-23","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":18910,"accession_number":"0001654954-26-006803","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces European Commission approval of Etcamah (camizestrant) in combination with CDK4/6 inhibitors for first-line ER-positive breast cancer, based on positive Phase III SERENA-6 trial results showing a 56% reduction in disease progression or death risk. This is a material regulatory milestone and product approval that would affect investor assessment of AstraZeneca's oncology pipeline and commercial prospects, but does not fit the discrete event categories (it is neither an earnings release, M\u0026A activity, nor a specific financial/governance event). The approval represents a significant operational and commercial achievement for the company's oncology business.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-23T10:07:28.069986+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-07-23"}]}